Seeking AlphaMon, 30 Mar 2026 20:20:39 GMTCorcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)CORT+0.50%
The Motley FoolFri, 27 Mar 2026 23:32:55 GMTWhy Corcept Therapeutics Zoomed Nearly 9% Higher This WeekCORT+0.50%
Zacks Investment ResearchThu, 26 Mar 2026 16:56:22 GMTCORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian CancerCORT+0.50%
Zacks Investment ResearchThu, 26 Mar 2026 16:32:55 GMTWhy Is Corcept (CORT) Up 11.7% Since Last Earnings Report?CORT+0.50%
The Motley FoolWed, 25 Mar 2026 20:36:46 GMTWhy Investors Strapped a Rocket to Corcept Therapeutics Stock on WednesdayCORT+0.50%
Zacks Investment ResearchThu, 05 Mar 2026 14:30:43 GMTCorcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?CORT+0.50%
Zacks Investment ResearchWed, 25 Feb 2026 15:15:59 GMTCorcept's Q4 Earnings and Revenues Fall Short of EstimatesCORT+0.50%
Zacks Investment ResearchWed, 25 Feb 2026 03:55:32 GMTCorcept Therapeutics (CORT) Q4 Earnings and Revenues Miss EstimatesCORT+0.50%
Seeking AlphaWed, 25 Feb 2026 00:47:53 GMTCorcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call TranscriptCORT+0.50%
Seeking AlphaFri, 20 Feb 2026 12:30:47 GMTCorcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is NotCORT+0.50%
Zacks Investment ResearchFri, 23 Jan 2026 17:16:06 GMTCORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer StudyCORT+0.50%
BenzingaThu, 22 Jan 2026 16:12:41 GMTCorcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock JumpsCORT+0.50%
